Last reviewed · How we verify
Severe Recalcitrant Psoriasis
Approved treatments
- Sandimmune · Novartis
- Sandimmune · Novartis AG (originally Sandoz)
Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection. - ciclosporine · Hospices Civils de Lyon
- Soriatane · Stiefel Labs Inc
- Oxsoralen-Ultra · Bausch Health
Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation. - Neoral · Novartis Pharmaceuticals
- Cyclosporin · Karolinska University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Severe Recalcitrant Psoriasis patent landscape — cliff calendar, originator estates, attackable patents
- Severe Recalcitrant Psoriasis treatment landscape brief
- Severe Recalcitrant Psoriasis treatment updates RSS
Frequently asked questions about Severe Recalcitrant Psoriasis
What drugs treat Severe Recalcitrant Psoriasis?
Tracked treatments include Sandimmune, ciclosporine, Soriatane, Oxsoralen-Ultra, Neoral, Cyclosporin.
What is the treatment for Severe Recalcitrant Psoriasis?
Standard treatment for Severe Recalcitrant Psoriasis includes Sandimmune, ciclosporine, Soriatane, Oxsoralen-Ultra, Neoral. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Severe Recalcitrant Psoriasis patent cliff · Severe Recalcitrant Psoriasis CI report
- Treatment: Sandimmune · Novartis
- Treatment: Sandimmune · Novartis AG (originally Sandoz)
- Treatment: ciclosporine · Hospices Civils de Lyon
- Treatment: Soriatane · Stiefel Labs Inc
- Treatment: Oxsoralen-Ultra · Bausch Health
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing